Companies › D3 Bio (Wuxi)
5 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Other; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| D3S-001 KRAS G12C inhibitor | KRAS | Phase 1 | KRAS P.G12C | Apr 2027 |
| D3L-002 Bispecific antibody targeting TIGIT and PVRIG | TIGIT, PVRIG | Phase 1 | Advanced Solid Tumor | Nov 2027 |
| D3S-003 KRAS G12D inhibitor | KRAS | Phase 1 | KRAS P.G12D | Jan 2028 |
| D3S-002 MAPK pathway inhibitor | – | Phase 1 | Advanced Solid Tumors With MAPK Pathway Mutations | Aug 2028 |
| D3L-001 Anti-HER2 antibody | ERBB2 | Phase 1 | HER-2 Positive Advanced Solid Tumors | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05410145 | D3S-001 | Phase 1 | KRAS P.G12C | Oncology | Apr 2027 |
| NCT07667842 | D3L-002 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2027 |
| NCT07456046 | D3S-003 | Phase 1 | KRAS P.G12D | Other | Jan 2028 |
| NCT05886920 | D3S-002 | Phase 1 | Advanced Solid Tumors With MAPK Pathway Mutations | Oncology | Aug 2028 |
| NCT05957536 | D3L-001 | Phase 1 | HER-2 Positive Advanced Solid Tumors | Oncology | Dec 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.